Whether or not you should buy APLS stock now is a personal decision. There are a number of factors to consider, including the company’s pipeline of drug candidates, its financial performance, its management team, the competitive landscape, and the regulatory environment.
Here are some of the pros and cons of buying APLS stock now:
The company has a number of promising drug candidates in its pipeline.
The company’s financial performance has been improving.
The company’s drug candidates are still in the early stages of development, so there is always the risk that they may not be successful.
The company is still relatively young and has not yet generated significant revenue.